nodes	percent_of_prediction	percent_of_DWPC	metapath
Esomeprazole—CYP2C19—Teniposide—lymphatic system cancer	0.176	0.393	CbGbCtD
Esomeprazole—CYP3A4—Cytarabine—lymphatic system cancer	0.0866	0.193	CbGbCtD
Esomeprazole—CYP3A4—Teniposide—lymphatic system cancer	0.0853	0.19	CbGbCtD
Esomeprazole—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0596	0.133	CbGbCtD
Esomeprazole—CYP3A4—Vincristine—lymphatic system cancer	0.041	0.0914	CbGbCtD
Esomeprazole—Chest pain—Bleomycin—lymphatic system cancer	0.000765	0.00139	CcSEcCtD
Esomeprazole—Myalgia—Bleomycin—lymphatic system cancer	0.000765	0.00139	CcSEcCtD
Esomeprazole—Alopecia—Vincristine—lymphatic system cancer	0.00076	0.00138	CcSEcCtD
Esomeprazole—Back pain—Carmustine—lymphatic system cancer	0.000759	0.00138	CcSEcCtD
Esomeprazole—Discomfort—Bleomycin—lymphatic system cancer	0.000756	0.00137	CcSEcCtD
Esomeprazole—Mental disorder—Vincristine—lymphatic system cancer	0.000753	0.00137	CcSEcCtD
Esomeprazole—Chills—Mitoxantrone—lymphatic system cancer	0.000751	0.00136	CcSEcCtD
Esomeprazole—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000751	0.00136	CcSEcCtD
Esomeprazole—Urine output increased—Methotrexate—lymphatic system cancer	0.000751	0.00136	CcSEcCtD
Esomeprazole—Neoplasm—Methotrexate—lymphatic system cancer	0.000751	0.00136	CcSEcCtD
Esomeprazole—Bladder pain—Methotrexate—lymphatic system cancer	0.000751	0.00136	CcSEcCtD
Esomeprazole—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000743	0.00135	CcSEcCtD
Esomeprazole—Alopecia—Mitoxantrone—lymphatic system cancer	0.00074	0.00134	CcSEcCtD
Esomeprazole—Confusional state—Bleomycin—lymphatic system cancer	0.000739	0.00134	CcSEcCtD
Esomeprazole—Vision blurred—Carmustine—lymphatic system cancer	0.000739	0.00134	CcSEcCtD
Esomeprazole—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000737	0.00134	CcSEcCtD
Esomeprazole—Tremor—Carmustine—lymphatic system cancer	0.000735	0.00133	CcSEcCtD
Esomeprazole—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000733	0.00133	CcSEcCtD
Esomeprazole—Infection—Bleomycin—lymphatic system cancer	0.000728	0.00132	CcSEcCtD
Esomeprazole—Anaemia—Carmustine—lymphatic system cancer	0.000725	0.00132	CcSEcCtD
Esomeprazole—Back pain—Vincristine—lymphatic system cancer	0.000724	0.00131	CcSEcCtD
Esomeprazole—Vomiting—Teniposide—lymphatic system cancer	0.000723	0.00131	CcSEcCtD
Esomeprazole—Agitation—Carmustine—lymphatic system cancer	0.000721	0.00131	CcSEcCtD
Esomeprazole—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000718	0.0013	CcSEcCtD
Esomeprazole—Asthenia—Fludarabine—lymphatic system cancer	0.000717	0.0013	CcSEcCtD
Esomeprazole—Rash—Teniposide—lymphatic system cancer	0.000717	0.0013	CcSEcCtD
Esomeprazole—Dermatitis—Teniposide—lymphatic system cancer	0.000717	0.0013	CcSEcCtD
Esomeprazole—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000714	0.0013	CcSEcCtD
Esomeprazole—Headache—Teniposide—lymphatic system cancer	0.000713	0.00129	CcSEcCtD
Esomeprazole—Pruritus—Fludarabine—lymphatic system cancer	0.000707	0.00128	CcSEcCtD
Esomeprazole—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000707	0.00128	CcSEcCtD
Esomeprazole—Back pain—Mitoxantrone—lymphatic system cancer	0.000705	0.00128	CcSEcCtD
Esomeprazole—Leukopenia—Carmustine—lymphatic system cancer	0.000702	0.00127	CcSEcCtD
Esomeprazole—Anorexia—Bleomycin—lymphatic system cancer	0.000699	0.00127	CcSEcCtD
Esomeprazole—Anaemia—Vincristine—lymphatic system cancer	0.000692	0.00126	CcSEcCtD
Esomeprazole—Agitation—Vincristine—lymphatic system cancer	0.000688	0.00125	CcSEcCtD
Esomeprazole—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000687	0.00125	CcSEcCtD
Esomeprazole—Polyuria—Methotrexate—lymphatic system cancer	0.000687	0.00125	CcSEcCtD
Esomeprazole—Photosensitivity—Methotrexate—lymphatic system cancer	0.000687	0.00125	CcSEcCtD
Esomeprazole—Diarrhoea—Fludarabine—lymphatic system cancer	0.000684	0.00124	CcSEcCtD
Esomeprazole—Hypertension—Carmustine—lymphatic system cancer	0.000677	0.00123	CcSEcCtD
Esomeprazole—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000676	0.00123	CcSEcCtD
Esomeprazole—Nausea—Teniposide—lymphatic system cancer	0.000676	0.00123	CcSEcCtD
Esomeprazole—Anaemia—Mitoxantrone—lymphatic system cancer	0.000674	0.00122	CcSEcCtD
Esomeprazole—Vertigo—Vincristine—lymphatic system cancer	0.000673	0.00122	CcSEcCtD
Esomeprazole—Hepatic failure—Methotrexate—lymphatic system cancer	0.000671	0.00122	CcSEcCtD
Esomeprazole—Leukopenia—Vincristine—lymphatic system cancer	0.00067	0.00122	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000668	0.00121	CcSEcCtD
Esomeprazole—Chest pain—Carmustine—lymphatic system cancer	0.000668	0.00121	CcSEcCtD
Esomeprazole—Myalgia—Carmustine—lymphatic system cancer	0.000668	0.00121	CcSEcCtD
Esomeprazole—Anxiety—Carmustine—lymphatic system cancer	0.000665	0.00121	CcSEcCtD
Esomeprazole—Paraesthesia—Bleomycin—lymphatic system cancer	0.000658	0.00119	CcSEcCtD
Esomeprazole—Malaise—Mitoxantrone—lymphatic system cancer	0.000657	0.00119	CcSEcCtD
Esomeprazole—Dyspnoea—Bleomycin—lymphatic system cancer	0.000654	0.00119	CcSEcCtD
Esomeprazole—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000653	0.00118	CcSEcCtD
Esomeprazole—Hypertension—Vincristine—lymphatic system cancer	0.000646	0.00117	CcSEcCtD
Esomeprazole—Confusional state—Carmustine—lymphatic system cancer	0.000645	0.00117	CcSEcCtD
Esomeprazole—Decreased appetite—Bleomycin—lymphatic system cancer	0.000637	0.00116	CcSEcCtD
Esomeprazole—Myalgia—Vincristine—lymphatic system cancer	0.000637	0.00116	CcSEcCtD
Esomeprazole—Visual disturbance—Methotrexate—lymphatic system cancer	0.000636	0.00115	CcSEcCtD
Esomeprazole—Cough—Mitoxantrone—lymphatic system cancer	0.000636	0.00115	CcSEcCtD
Esomeprazole—Infection—Carmustine—lymphatic system cancer	0.000636	0.00115	CcSEcCtD
Esomeprazole—Vomiting—Fludarabine—lymphatic system cancer	0.000636	0.00115	CcSEcCtD
Esomeprazole—Rash—Fludarabine—lymphatic system cancer	0.000631	0.00114	CcSEcCtD
Esomeprazole—Dermatitis—Fludarabine—lymphatic system cancer	0.00063	0.00114	CcSEcCtD
Esomeprazole—Hypertension—Mitoxantrone—lymphatic system cancer	0.000629	0.00114	CcSEcCtD
Esomeprazole—Pain—Bleomycin—lymphatic system cancer	0.000627	0.00114	CcSEcCtD
Esomeprazole—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000627	0.00114	CcSEcCtD
Esomeprazole—Headache—Fludarabine—lymphatic system cancer	0.000626	0.00114	CcSEcCtD
Esomeprazole—Tachycardia—Carmustine—lymphatic system cancer	0.000625	0.00113	CcSEcCtD
Esomeprazole—Myalgia—Mitoxantrone—lymphatic system cancer	0.000621	0.00113	CcSEcCtD
Esomeprazole—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000621	0.00113	CcSEcCtD
Esomeprazole—Chest pain—Mitoxantrone—lymphatic system cancer	0.000621	0.00113	CcSEcCtD
Esomeprazole—Anxiety—Mitoxantrone—lymphatic system cancer	0.000619	0.00112	CcSEcCtD
Esomeprazole—Discomfort—Mitoxantrone—lymphatic system cancer	0.000613	0.00111	CcSEcCtD
Esomeprazole—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000611	0.00111	CcSEcCtD
Esomeprazole—Anorexia—Carmustine—lymphatic system cancer	0.00061	0.00111	CcSEcCtD
Esomeprazole—Infection—Vincristine—lymphatic system cancer	0.000607	0.0011	CcSEcCtD
Esomeprazole—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000604	0.0011	CcSEcCtD
Esomeprazole—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000603	0.00109	CcSEcCtD
Esomeprazole—Confusional state—Mitoxantrone—lymphatic system cancer	0.0006	0.00109	CcSEcCtD
Esomeprazole—Nervous system disorder—Vincristine—lymphatic system cancer	0.000599	0.00109	CcSEcCtD
Esomeprazole—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000598	0.00109	CcSEcCtD
Esomeprazole—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000595	0.00108	CcSEcCtD
Esomeprazole—Nausea—Fludarabine—lymphatic system cancer	0.000594	0.00108	CcSEcCtD
Esomeprazole—Infection—Mitoxantrone—lymphatic system cancer	0.000591	0.00107	CcSEcCtD
Esomeprazole—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000591	0.00107	CcSEcCtD
Esomeprazole—Shock—Mitoxantrone—lymphatic system cancer	0.000585	0.00106	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000583	0.00106	CcSEcCtD
Esomeprazole—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000583	0.00106	CcSEcCtD
Esomeprazole—Urticaria—Bleomycin—lymphatic system cancer	0.000582	0.00106	CcSEcCtD
Esomeprazole—Anorexia—Vincristine—lymphatic system cancer	0.000582	0.00106	CcSEcCtD
Esomeprazole—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000581	0.00105	CcSEcCtD
Esomeprazole—Body temperature increased—Bleomycin—lymphatic system cancer	0.00058	0.00105	CcSEcCtD
Esomeprazole—Insomnia—Carmustine—lymphatic system cancer	0.000579	0.00105	CcSEcCtD
Esomeprazole—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000578	0.00105	CcSEcCtD
Esomeprazole—Irritability—Methotrexate—lymphatic system cancer	0.000576	0.00104	CcSEcCtD
Esomeprazole—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000575	0.00104	CcSEcCtD
Esomeprazole—Paraesthesia—Carmustine—lymphatic system cancer	0.000575	0.00104	CcSEcCtD
Esomeprazole—Dyspnoea—Carmustine—lymphatic system cancer	0.000571	0.00104	CcSEcCtD
Esomeprazole—Somnolence—Carmustine—lymphatic system cancer	0.000569	0.00103	CcSEcCtD
Esomeprazole—Anorexia—Mitoxantrone—lymphatic system cancer	0.000567	0.00103	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000557	0.00101	CcSEcCtD
Esomeprazole—Decreased appetite—Carmustine—lymphatic system cancer	0.000556	0.00101	CcSEcCtD
Esomeprazole—Insomnia—Vincristine—lymphatic system cancer	0.000553	0.001	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000553	0.001	CcSEcCtD
Esomeprazole—Paraesthesia—Vincristine—lymphatic system cancer	0.000549	0.000995	CcSEcCtD
Esomeprazole—Pain—Carmustine—lymphatic system cancer	0.000547	0.000993	CcSEcCtD
Esomeprazole—Constipation—Carmustine—lymphatic system cancer	0.000547	0.000993	CcSEcCtD
Esomeprazole—Breast disorder—Methotrexate—lymphatic system cancer	0.000545	0.000989	CcSEcCtD
Esomeprazole—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000543	0.000986	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000542	0.000984	CcSEcCtD
Esomeprazole—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00054	0.00098	CcSEcCtD
Esomeprazole—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000534	0.000969	CcSEcCtD
Esomeprazole—Decreased appetite—Vincristine—lymphatic system cancer	0.000531	0.000964	CcSEcCtD
Esomeprazole—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00053	0.000963	CcSEcCtD
Esomeprazole—Somnolence—Mitoxantrone—lymphatic system cancer	0.000529	0.00096	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000527	0.000957	CcSEcCtD
Esomeprazole—Feeling abnormal—Carmustine—lymphatic system cancer	0.000527	0.000957	CcSEcCtD
Esomeprazole—Fatigue—Vincristine—lymphatic system cancer	0.000527	0.000956	CcSEcCtD
Esomeprazole—Asthenia—Bleomycin—lymphatic system cancer	0.000526	0.000955	CcSEcCtD
Esomeprazole—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000524	0.00095	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000523	0.00095	CcSEcCtD
Esomeprazole—Pain—Vincristine—lymphatic system cancer	0.000522	0.000948	CcSEcCtD
Esomeprazole—Constipation—Vincristine—lymphatic system cancer	0.000522	0.000948	CcSEcCtD
Esomeprazole—Asthma—Methotrexate—lymphatic system cancer	0.000521	0.000946	CcSEcCtD
Esomeprazole—Pruritus—Bleomycin—lymphatic system cancer	0.000519	0.000941	CcSEcCtD
Esomeprazole—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000517	0.000939	CcSEcCtD
Esomeprazole—Fatigue—Mitoxantrone—lymphatic system cancer	0.000513	0.000931	CcSEcCtD
Esomeprazole—Pancreatitis—Methotrexate—lymphatic system cancer	0.000511	0.000927	CcSEcCtD
Esomeprazole—Pain—Mitoxantrone—lymphatic system cancer	0.000509	0.000923	CcSEcCtD
Esomeprazole—Constipation—Mitoxantrone—lymphatic system cancer	0.000509	0.000923	CcSEcCtD
Esomeprazole—Abdominal pain—Carmustine—lymphatic system cancer	0.000506	0.000918	CcSEcCtD
Esomeprazole—Body temperature increased—Carmustine—lymphatic system cancer	0.000506	0.000918	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.0005	0.000907	CcSEcCtD
Esomeprazole—Pancytopenia—Methotrexate—lymphatic system cancer	0.000495	0.000898	CcSEcCtD
Esomeprazole—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00049	0.00089	CcSEcCtD
Esomeprazole—Neutropenia—Methotrexate—lymphatic system cancer	0.000487	0.000885	CcSEcCtD
Esomeprazole—Dysuria—Methotrexate—lymphatic system cancer	0.000487	0.000885	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000487	0.000883	CcSEcCtD
Esomeprazole—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000484	0.000879	CcSEcCtD
Esomeprazole—Abdominal pain—Vincristine—lymphatic system cancer	0.000483	0.000876	CcSEcCtD
Esomeprazole—Body temperature increased—Vincristine—lymphatic system cancer	0.000483	0.000876	CcSEcCtD
Esomeprazole—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00048	0.000871	CcSEcCtD
Esomeprazole—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000476	0.000863	CcSEcCtD
Esomeprazole—Urticaria—Mitoxantrone—lymphatic system cancer	0.000473	0.000858	CcSEcCtD
Esomeprazole—Hypersensitivity—Carmustine—lymphatic system cancer	0.000472	0.000856	CcSEcCtD
Esomeprazole—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00047	0.000853	CcSEcCtD
Esomeprazole—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00047	0.000853	CcSEcCtD
Esomeprazole—Vomiting—Bleomycin—lymphatic system cancer	0.000466	0.000846	CcSEcCtD
Esomeprazole—Infestation NOS—Methotrexate—lymphatic system cancer	0.000465	0.000843	CcSEcCtD
Esomeprazole—Infestation—Methotrexate—lymphatic system cancer	0.000465	0.000843	CcSEcCtD
Esomeprazole—Depression—Methotrexate—lymphatic system cancer	0.000463	0.000841	CcSEcCtD
Esomeprazole—Rash—Bleomycin—lymphatic system cancer	0.000462	0.000839	CcSEcCtD
Esomeprazole—Dermatitis—Bleomycin—lymphatic system cancer	0.000462	0.000838	CcSEcCtD
Esomeprazole—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000461	0.000836	CcSEcCtD
Esomeprazole—Asthenia—Carmustine—lymphatic system cancer	0.000459	0.000833	CcSEcCtD
Esomeprazole—Renal failure—Methotrexate—lymphatic system cancer	0.000457	0.000829	CcSEcCtD
Esomeprazole—Stomatitis—Methotrexate—lymphatic system cancer	0.000453	0.000822	CcSEcCtD
Esomeprazole—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000452	0.00082	CcSEcCtD
Esomeprazole—Hypersensitivity—Vincristine—lymphatic system cancer	0.00045	0.000817	CcSEcCtD
Esomeprazole—Haematuria—Methotrexate—lymphatic system cancer	0.000443	0.000804	CcSEcCtD
Esomeprazole—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00044	0.000798	CcSEcCtD
Esomeprazole—Epistaxis—Methotrexate—lymphatic system cancer	0.000438	0.000796	CcSEcCtD
Esomeprazole—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000438	0.000795	CcSEcCtD
Esomeprazole—Asthenia—Vincristine—lymphatic system cancer	0.000438	0.000795	CcSEcCtD
Esomeprazole—Diarrhoea—Carmustine—lymphatic system cancer	0.000438	0.000795	CcSEcCtD
Esomeprazole—Nausea—Bleomycin—lymphatic system cancer	0.000436	0.00079	CcSEcCtD
Esomeprazole—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000434	0.000787	CcSEcCtD
Esomeprazole—Asthenia—Mitoxantrone—lymphatic system cancer	0.000427	0.000775	CcSEcCtD
Esomeprazole—Dizziness—Carmustine—lymphatic system cancer	0.000423	0.000768	CcSEcCtD
Esomeprazole—Diarrhoea—Vincristine—lymphatic system cancer	0.000418	0.000759	CcSEcCtD
Esomeprazole—Hepatitis—Methotrexate—lymphatic system cancer	0.000417	0.000757	CcSEcCtD
Esomeprazole—Pharyngitis—Methotrexate—lymphatic system cancer	0.000414	0.000751	CcSEcCtD
Esomeprazole—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000412	0.000748	CcSEcCtD
Esomeprazole—Urethral disorder—Methotrexate—lymphatic system cancer	0.000409	0.000742	CcSEcCtD
Esomeprazole—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000407	0.000739	CcSEcCtD
Esomeprazole—Vomiting—Carmustine—lymphatic system cancer	0.000407	0.000738	CcSEcCtD
Esomeprazole—Dizziness—Vincristine—lymphatic system cancer	0.000404	0.000733	CcSEcCtD
Esomeprazole—Rash—Carmustine—lymphatic system cancer	0.000404	0.000732	CcSEcCtD
Esomeprazole—Dermatitis—Carmustine—lymphatic system cancer	0.000403	0.000732	CcSEcCtD
Esomeprazole—Visual impairment—Methotrexate—lymphatic system cancer	0.000402	0.00073	CcSEcCtD
Esomeprazole—Headache—Carmustine—lymphatic system cancer	0.000401	0.000728	CcSEcCtD
Esomeprazole—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000395	0.000716	CcSEcCtD
Esomeprazole—Eye disorder—Methotrexate—lymphatic system cancer	0.00039	0.000708	CcSEcCtD
Esomeprazole—Tinnitus—Methotrexate—lymphatic system cancer	0.000389	0.000706	CcSEcCtD
Esomeprazole—Vomiting—Vincristine—lymphatic system cancer	0.000388	0.000705	CcSEcCtD
Esomeprazole—Rash—Vincristine—lymphatic system cancer	0.000385	0.000699	CcSEcCtD
Esomeprazole—Dermatitis—Vincristine—lymphatic system cancer	0.000385	0.000698	CcSEcCtD
Esomeprazole—Headache—Vincristine—lymphatic system cancer	0.000383	0.000695	CcSEcCtD
Esomeprazole—Nausea—Carmustine—lymphatic system cancer	0.00038	0.00069	CcSEcCtD
Esomeprazole—Vomiting—Mitoxantrone—lymphatic system cancer	0.000378	0.000686	CcSEcCtD
Esomeprazole—Immune system disorder—Methotrexate—lymphatic system cancer	0.000377	0.000684	CcSEcCtD
Esomeprazole—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000376	0.000682	CcSEcCtD
Esomeprazole—Rash—Mitoxantrone—lymphatic system cancer	0.000375	0.000681	CcSEcCtD
Esomeprazole—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000375	0.00068	CcSEcCtD
Esomeprazole—Chills—Methotrexate—lymphatic system cancer	0.000374	0.000679	CcSEcCtD
Esomeprazole—Headache—Mitoxantrone—lymphatic system cancer	0.000373	0.000676	CcSEcCtD
Esomeprazole—Alopecia—Methotrexate—lymphatic system cancer	0.000369	0.000669	CcSEcCtD
Esomeprazole—Mental disorder—Methotrexate—lymphatic system cancer	0.000366	0.000663	CcSEcCtD
Esomeprazole—Malnutrition—Methotrexate—lymphatic system cancer	0.000363	0.000659	CcSEcCtD
Esomeprazole—Nausea—Vincristine—lymphatic system cancer	0.000363	0.000659	CcSEcCtD
Esomeprazole—Dysgeusia—Methotrexate—lymphatic system cancer	0.000356	0.000645	CcSEcCtD
Esomeprazole—Nausea—Mitoxantrone—lymphatic system cancer	0.000353	0.000641	CcSEcCtD
Esomeprazole—Back pain—Methotrexate—lymphatic system cancer	0.000351	0.000638	CcSEcCtD
Esomeprazole—Vision blurred—Methotrexate—lymphatic system cancer	0.000342	0.000621	CcSEcCtD
Esomeprazole—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000337	0.000612	CcSEcCtD
Esomeprazole—Anaemia—Methotrexate—lymphatic system cancer	0.000336	0.000609	CcSEcCtD
Esomeprazole—Malaise—Methotrexate—lymphatic system cancer	0.000328	0.000594	CcSEcCtD
Esomeprazole—Vertigo—Methotrexate—lymphatic system cancer	0.000326	0.000592	CcSEcCtD
Esomeprazole—Leukopenia—Methotrexate—lymphatic system cancer	0.000325	0.00059	CcSEcCtD
Esomeprazole—Cough—Methotrexate—lymphatic system cancer	0.000317	0.000575	CcSEcCtD
Esomeprazole—Myalgia—Methotrexate—lymphatic system cancer	0.000309	0.000561	CcSEcCtD
Esomeprazole—Arthralgia—Methotrexate—lymphatic system cancer	0.000309	0.000561	CcSEcCtD
Esomeprazole—Chest pain—Methotrexate—lymphatic system cancer	0.000309	0.000561	CcSEcCtD
Esomeprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000307	0.000557	CcSEcCtD
Esomeprazole—Discomfort—Methotrexate—lymphatic system cancer	0.000306	0.000554	CcSEcCtD
Esomeprazole—Confusional state—Methotrexate—lymphatic system cancer	0.000299	0.000542	CcSEcCtD
Esomeprazole—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000296	0.000538	CcSEcCtD
Esomeprazole—Infection—Methotrexate—lymphatic system cancer	0.000295	0.000534	CcSEcCtD
Esomeprazole—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000291	0.000528	CcSEcCtD
Esomeprazole—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00029	0.000527	CcSEcCtD
Esomeprazole—Skin disorder—Methotrexate—lymphatic system cancer	0.000288	0.000523	CcSEcCtD
Esomeprazole—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000287	0.00052	CcSEcCtD
Esomeprazole—Anorexia—Methotrexate—lymphatic system cancer	0.000283	0.000513	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00027	0.00049	CcSEcCtD
Esomeprazole—Insomnia—Methotrexate—lymphatic system cancer	0.000268	0.000487	CcSEcCtD
Esomeprazole—Paraesthesia—Methotrexate—lymphatic system cancer	0.000266	0.000483	CcSEcCtD
Esomeprazole—Dyspnoea—Methotrexate—lymphatic system cancer	0.000264	0.00048	CcSEcCtD
Esomeprazole—Somnolence—Methotrexate—lymphatic system cancer	0.000264	0.000478	CcSEcCtD
Esomeprazole—Dyspepsia—Methotrexate—lymphatic system cancer	0.000261	0.000474	CcSEcCtD
Esomeprazole—Decreased appetite—Methotrexate—lymphatic system cancer	0.000258	0.000468	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000256	0.000464	CcSEcCtD
Esomeprazole—Fatigue—Methotrexate—lymphatic system cancer	0.000256	0.000464	CcSEcCtD
Esomeprazole—Pain—Methotrexate—lymphatic system cancer	0.000254	0.00046	CcSEcCtD
Esomeprazole—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000244	0.000443	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000242	0.00044	CcSEcCtD
Esomeprazole—Urticaria—Methotrexate—lymphatic system cancer	0.000236	0.000427	CcSEcCtD
Esomeprazole—Abdominal pain—Methotrexate—lymphatic system cancer	0.000234	0.000425	CcSEcCtD
Esomeprazole—Body temperature increased—Methotrexate—lymphatic system cancer	0.000234	0.000425	CcSEcCtD
Esomeprazole—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000218	0.000396	CcSEcCtD
Esomeprazole—Asthenia—Methotrexate—lymphatic system cancer	0.000213	0.000386	CcSEcCtD
Esomeprazole—Pruritus—Methotrexate—lymphatic system cancer	0.00021	0.000381	CcSEcCtD
Esomeprazole—Diarrhoea—Methotrexate—lymphatic system cancer	0.000203	0.000368	CcSEcCtD
Esomeprazole—Dizziness—Methotrexate—lymphatic system cancer	0.000196	0.000356	CcSEcCtD
Esomeprazole—Vomiting—Methotrexate—lymphatic system cancer	0.000188	0.000342	CcSEcCtD
Esomeprazole—Rash—Methotrexate—lymphatic system cancer	0.000187	0.000339	CcSEcCtD
Esomeprazole—Dermatitis—Methotrexate—lymphatic system cancer	0.000187	0.000339	CcSEcCtD
Esomeprazole—Headache—Methotrexate—lymphatic system cancer	0.000186	0.000337	CcSEcCtD
Esomeprazole—Nausea—Methotrexate—lymphatic system cancer	0.000176	0.00032	CcSEcCtD
